Eli Lilly reported impressive first-quarter earnings, surpassing analyst expectations with adjusted earnings per share of $8.55 and revenue of $19.80 billion, leading to a $2 billion increase in its full-year sales outlook. The pharmaceutical company anticipates 2026 revenue between $82 billion and $85 billion, driven by robust demand for its weight loss drug Zepbound and diabetes treatment Mounjaro, which saw a 125% increase in worldwide revenue to $8.66 billion.
This strong performance underscores Lilly’s dominance in the GLP-1 drug market, where it holds a 60.1% share, significantly outpacing competitor Novo Nordisk. Despite facing pricing pressures, Lilly’s strategy to maintain volume growth through lower prices appears effective, as evidenced by a 49% increase in prescription volume for its leading products. The company’s net income surged to $7.40 billion, reflecting a solid year-over-year growth trajectory.
For market professionals, the key takeaway is that Lilly’s robust earnings and revised guidance signal continued strength in the GLP-1 sector, making it a stock to watch as it navigates competitive dynamics and pricing strategies in the coming quarters.
Source: cnbc.com